We are live on ! Find out more
PCM

Pavaki Capital Management Portfolio holdings

AUM $287M
This Fund
S&P 500
This Quarter Est. Return
+0.76%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$235M
AUM Growth
-$19.8M
Cap. Flow
+$10.3M
Cap. Flow %
4.36%
Top 10 Hldgs %
50.47%
Holding
162
New
31
Increased
16
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
CVX icon
Chevron
CVX
+$13.2M
2
EWS icon
iShares MSCI Singapore ETF
EWS
+$1.69M
3
ESPR
Esperion Therapeutics
ESPR
+$1.3M
4
B
Barrick Mining
B
+$1.27M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$1.19M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.8M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$5.71M
3
OGN icon
Organon & Co
OGN
+$3.01M
4
ROIV icon
Roivant Sciences
ROIV
+$868K
5
ALT icon
Altimmune
ALT
+$778K

Sector Composition

Rank Sector Weight
1 Miscellaneous 41.44%
2 Healthcare 20.32%
3 Materials 13.21%
4 Energy 8.84%
5 Technology 4.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OGN icon
26
Organon & Co
OGN
$3.61B
$1.97M 0.83%
328,100
-400,000
-55% -$3.01M
PSKY
27
Paramount Skydance Corp
PSKY
$11.2B
$1.88M 0.8%
208,863
– –
ORLY icon
28
CALL
O'Reilly Automotive
ORLY
$69.6B
$1.77M 0.75%
19,200
– –
EWS icon
29
iShares MSCI Singapore ETF
EWS
$1.4B
$1.69M 0.72%
+60,000
New +$1.69M
AZO icon
30
CALL
AutoZone
AZO
$46.5B
$1.69M 0.72%
500
– –
BIO icon
31
Bio-Rad Laboratories Class A
BIO
$10.1B
$1.67M 0.71%
6,000
– –
DOUG icon
32
Douglas Elliman
DOUG
$138M
$1.66M 0.71%
1,013,752
+200
+0% +$464
KGC icon
33
Kinross Gold
KGC
$28.8B
$1.51M 0.64%
49,500
– –
CRM icon
34
CALL
Salesforce
CRM
$185B
$1.49M 0.63%
8,000
– –
YUMC icon
35
Yum China
YUMC
$13.8B
$1.46M 0.62%
30,000
– –
BIDU icon
36
Baidu
BIDU
$29.5B
$1.45M 0.62%
13,000
– –
EQX icon
37
Equinox Gold
EQX
$13.3B
$1.45M 0.61%
100,000
– –
SNDX icon
38
Syndax Pharmaceuticals
SNDX
$1.63B
$1.4M 0.6%
60,000
– –
SPHR icon
39
Sphere Entertainment
SPHR
$4.82B
$1.39M 0.59%
11,860
– –
TOL icon
40
PUT
Toll Brothers
TOL
$12.5B
$1.36M 0.58%
10,000
– –
PLTR icon
41
PUT
Palantir
PLTR
$449B
$1.32M 0.56%
9,000
– –
EPHE icon
42
iShares MSCI Philippines ETF
EPHE
$132M
$1.19M 0.51%
48,000
+30,000
+167% +$781K
NAMS icon
43
NewAmsterdam Pharma
NAMS
$2.85B
$1.17M 0.5%
+36,600
New +$1.19M
ESPR
44
DELISTED
Esperion Therapeutics
ESPR
$1.12M 0.48%
+410,000
New +$1.3M
HPE icon
45
Hewlett Packard
HPE
$81.6B
$976K 0.41%
41,000
– –
BBD icon
46
Banco Bradesco
BBD
$35.6B
$965K 0.41%
264,336
+20,000
+8% +$75.8K
SNY icon
47
Sanofi
SNY
$97.6B
$964K 0.41%
20,000
– –
RGLD icon
48
Royal Gold
RGLD
$20.2B
$954K 0.41%
3,750
– –
CVNA icon
49
PUT
Carvana
CVNA
$45.8B
$943K 0.4%
15,000
-30,000
-67% -$2.23M
ORCL icon
50
CALL
Oracle
ORCL
$418B
$883K 0.38%
6,000
– –
1
2
3 4 5

Similar funds

OCM
Ogborne Capital Management San Francisco, California $287M AUM 14.05% 1-Year Est. Return
RSC
Red Spruce Capital Berwyn, Pennsylvania $287M AUM 38.81% 1-Year Est. Return
MC
Metavasi Capital Larchmont, New York $287M AUM 97.9% 1-Year Est. Return
QFW
QTR Family Wealth Lake Mary, Florida $287M AUM 40.55% 1-Year Est. Return
SRWM
Shira Ridge Wealth Management Larkspur, California $287M AUM 23.34% 1-Year Est. Return
ORC
O'Rourke & Company Boston, Massachusetts $287M AUM 23.01% 1-Year Est. Return
MPAM
Murphy Pohlad Asset Management Eden Prairie, Minnesota $287M AUM 38.81% 1-Year Est. Return
AWMT
AAFMAA Wealth Management & Trust Fayetteville, North Carolina $286M AUM 19.57% 1-Year Est. Return

Pavaki Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Pavaki Capital Management held 162 positions worth $235M, down 7.8% from $255M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Pavaki Capital Management deployed $10.3M of net new capital in Q1 2026, opening 31 new positions and adding to 16 existing holdings. Its largest new stake was iShares MSCI Singapore ETF: 60,000 shares worth $1.69M.

By sector, the portfolio is most concentrated in Miscellaneous at 41% of assets, down from 44% a quarter earlier, followed by Healthcare and Materials.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $8.8M trimmed.

  • Pavaki Capital Management's largest Q1 2026 buy was iShares MSCI Singapore ETF: 60,000 shares worth $1.69M.
  • Pavaki Capital Management added most to Chevron in Q1 2026, an estimated $13.2M increase.
  • Pavaki Capital Management's biggest Q1 2026 reduction was Regeneron Pharmaceuticals, cutting an estimated $8.8M.
  • Pavaki Capital Management fully exited Roivant Sciences in Q1 2026, selling an estimated $868K.
  • Pavaki Capital Management's ten largest holdings make up 50% of its $235M portfolio in Q1 2026.
  • Pavaki Capital Management opened 31 new positions and closed 6 in Q1 2026.
  • Pavaki Capital Management's portfolio value fell 7.8% quarter-over-quarter to $235M.

Based on Pavaki Capital Management's 13F filing for Q1 2026, filed 7 Aug 2026.